All four T-ALL cell lines employed in this study—Jurkat, Molt-4, DND-41, and ALL-SIL—have been reported in the literature to have constitutive aberrant activation of the PI3K/Akt pathway, although through distinct mechanisms [7,8]. The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.